Drug intelligence / Profile preview

TAK-279 + efavirenz

Development stage: Unknown
Lead developer: Takeda
Modality: Small Molecules
Administration: Oral

Overview

**TAK-279 + efavirenz** is a combination of TAK-279 (zasocitinib), a highly selective oral allosteric inhibitor of Tyrosine kinase 2 (TYK2), and efavirenz, a non-nucleoside reverse transcriptase inhibitor (NNRTI) used in HIV therapy. TAK-279 is being investigated for immune-mediated inflammatory diseases such as psoriatic arthritis, while efavirenz is an approved antiretroviral for HIV-1 infection. The combination is primarily studied to investigate drug–drug interactions, specifically how the strong CYP3A4 inducer efavirenz affects the pharmacokinetics of TAK-279 in healthy participants[1][3][5][6].

Brand names: SustivaStocrinAtripla
Other names: zasocitinibDMP 266DMP266DMP-266

Targets

Human immunodeficiency virus type 1 reverse transcriptase

Beyond the preview

Go deeper on TAK-279 + efavirenz.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TAK-279 + efavirenz.

Explore the full profile